Nonspecific resistance-enhancing activity of zymosan in experimental bacterial infections.
The nonspecific resistance-enhancing activity of zymosan on experimental bacterial (Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Serratia marcescens and Staphylococcus aureus) infections was investigated. Zymosan, being of very low toxicity, significantly enhanced nonspecific resistance to the above bacteria. The enhancement was the most pronounced 2 to 5 days after zymosan treatment.
Emöd
J
J
WHO Collaborating Centre for Reference and Research on Bacterial Vaccines, Human Institute for Serobacteriological Production and Research, Budapest, Hungary.
Joó
I
I
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D000818:Animals; D001424:Bacterial Infections / Q000276:immunology / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D004756:Enterobacteriaceae Infections / Q000628:therapy; D005260:Female; D007928:Lethal Dose 50; D008297:Male; D051379:Mice; D011552:Pseudomonas Infections / Q000628:therapy; D013203:Staphylococcal Infections / Q000628:therapy; D015054:Zymosan / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity
D000276:Adjuvants, Immunologic; D015054:Zymosan